PTC Therapeutics (PTCT) PT Raised to $85 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts PTCT Hot Sheet
Price: $68.12 --0%
Rating Summary:
17 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Rating Summary:
17 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Join SI Premium – FREE
RBC Capital analyst Brian Abrahams raised the price target on PTC Therapeutics (NASDAQ: PTCT) to $85.00 (from $82.00) while maintaining a Sector Perform rating.
You May Also Be Interested In
- Truist on PTC Therapeutics (PTCT): 'we continue to believe this will be an uphill battle for the company'
- Bayer AG (BAYN:GR) (BAYRY) PT Raised to EUR56 at BMO Capital
- Eureka Forbes Ltd (EUREKAFO:IN) PT Lowered to INR457 at Axis Capital Limited
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
